Omecamtiv mecarbil, a cardiac muscle activator for the potential treatment of heart failure. In May 2024, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In Novemb… WebMay 6, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision. ... and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates …
PRESS RELEASES Cytokinetics, Inc.
WebApr 11, 2024 · The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six new products with “sizable markets.” ... Cytokinetics (CYTK) Dips 20% so Far in 2024 on ... WebFeb 28, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete... each new way of looking
AMENDMENT NO. 6 TO COLLABORATION AND OPTION …
WebProducts. Product Types. Antibodies; Buffers and Solutions; Cell Culture Media and Supplements; Cell Dyes and Detection Assay Kits; Cell Engineering and Molecular … WebFeb 23, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. WebSep 23, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. each new year